Biotech company PharmAust (ASX: PAA) has been invited by not-for-profit organisation FightMND to submit a comprehensive grant application which could grant up to $1.8 million to fund Phase 2 and 3 clinical trials in an effort to find a treatment for Motor Neurone Disease (MND) Earlier this month, PharmAust submitted a Letter of Intent to
Read More
12-year-old Louie the beagle had little time left once the vet diagnosed his lymphoma. To avoid the side effects of steroids and chemo, his parents took a chance on biotech company PharmAust’s (ASX: PAA) monepantel (MPL) drug. Within a few weeks, Louie’s lymph nodes shrunk and he enjoyed a good quality of life. Today, he
Read More
Every day, two people are diagnosed in Australia with a form of motor neurone disease (MND). MND entails a group of diseases that attack your motor nerves, leaving your muscles to become weak and degenerate. According to the International Alliance of ALS/MND Associations, MND affects over 350,000 people globally and kills over 100,000 people every
Read More
As I write this there’s a tiny senior chihuahua with half an ear snuggled up on my lap, a jack russell sitting at my feet and a kelpie lounging on the couch. The four leggeds outnumber the humans and I wouldn’t have it any other way. Dogs in all their snuggly, wiggly glory are simply the
Read More
Ever wondered how renewable fuel is made? Or how biodegradable plastics are created? There’s a lot that happens after you throw something away, and the process of repurposing materials is more complex than you might think. Clinical stage oncology company PharmAust (ASX: PAA) has an interesting subsidiary involved in just that. Epichem is a leading
Read More
Good things come in small packages, like PharmAust’s (ASX: PAA) newest iteration of their monepantel (MPL) tablets. The clinical stage biotechnology company has manufactured smaller versions of their lead asset, MPL, a potent small molecule drug that has been shown to affect key pathways associated with cancer and other diseases. PharmAust have studied MPL for
Read More